Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), COSCO Shipping Holdings (01919), and Heng Rui Medicine (01276), with short ratios of 19.04%, 17.09%, and 15.18% respectively [1][2] - The companies with the largest absolute increase in short positions are Zhaoyan New Drug (06127), Lens Technology (06613), and China Everbright Holdings (00165), with increases of 2.08%, 1.68%, and 1.46% respectively [1][2] - The companies with the largest absolute decrease in short positions are ZTE Corporation (00763), Nuo Cheng Jian Hua (09969), and Yi Mai Tong (02192), with decreases of -3.12%, -2.21%, and -1.70% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Vanke Enterprises (02202) at 19.04%, COSCO Shipping Holdings (01919) at 17.09%, and Heng Rui Medicine (01276) at 15.18% [2] - The companies with the most significant increase in short ratios include Zhaoyan New Drug (06127) from 3.50% to 5.57%, Lens Technology (06613) from 3.07% to 4.75%, and China Everbright Holdings (00165) from 2.04% to 3.51% [2] - The companies with the most significant decrease in short ratios include ZTE Corporation (00763) from 17.63% to 14.51%, Nuo Cheng Jian Hua (09969) from 5.19% to 2.97%, and Yi Mai Tong (02192) from 3.06% to 1.36% [2][3]

格隆汇勾股大数据显示，招商恒生科技（03423），中国光大控股（00165），GX恒生高股息率 （03110），红星美凯龙（01528），中远海能（01138）港股通五日资金显著流入，五日持仓占比变动 分别为，3.23%，2.37%，2.35%，2.19%，2.05%。此外，招商证券（06099），医脉通（02192），东方 电气（01072），狮腾控股（02562），猫眼娱乐（01896）港股通五日资金显著流出，五日资金显著流 出，五日持仓占比变动分别为，-3.89%，-2.95%，-2.23%，-2.21%，-1.90%。 五日资金流入榜 备注：以上数据由格隆汇数据中心根据港交所数据加工计算所得，并不保证100%精确。 港股通数据为T+2数据，即今日披露数据为前两个交易日数据。 股票名称 港股通五日持仓占比变动 累计持仓占比 净流入金额（百万） 净买入股数（万股) 招商恒生科 技(03423) 3.23% 5.17% 2.630 26.11 中国光大控股(00165) 2.37% 28.2008% 516.262 4662.20 GX恒生高股 息率(03110) 2.35% 2.35% -0.959 -2 ...

12月12日,美团-W（03690）、小米集团-W（01810）、贝壳-W（02423）南向资金净流入金额位列市场 前三，分别净流入24.76 亿、23.53 亿、9.41 亿 阿里巴巴-W（09988）、腾讯控股（00700）、华虹半导体（01347）南向资金净流出金额位列市场前 三，分别净流出-33.73 亿、-9.98 亿、-7.35 亿 在净流入比方面，中国光大控股（00165）、中远海能（01138）、华润燃气（01193）以70.94%、 69.71%、69.27%位列市场前三。 在净流出比方面，猫眼娱乐（01896）、招商证券（06099）、医脉通（02192） 以-75.39%、-71.19%、-69.31%位列市场前三。 前10大净流出比榜 | 股票名称 | 净流出比↓ | 净流出(元) | 收盘价 | | --- | --- | --- | --- | | 猫眼娱乐(01896) | -75.39% | -1.92 亿 | 7.190（+3.45%） | | 招商证券(06099) | -71.19% | -6.00 亿 | 13.510（+0.82%） | | 医脉通(02192) | ...

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of 1.125 million shares due to the exercise of stock options on December 11, 2025 [1] Summary by Category - **Company Announcement** - 医脉通 will issue 1.125 million shares as a result of stock option exercises [1]

Core Points - The company, 医脉通 (Medlinker), announced the issuance of 1.125 million shares due to the exercise of stock options on December 11, 2025 [1] Company Summary - 医脉通 (Medlinker) is set to issue 1.125 million shares as a result of stock option exercises, indicating potential changes in equity structure and shareholder composition [1]

Core Viewpoint - The company, 医脉通 (02192.HK), announced the issuance of 1.1 million ordinary shares to three directors and 25,000 ordinary shares to one employee as part of its pre-IPO share option plan adopted on March 29, 2021, with the issuance date set for December 11, 2025 [1]. Group 1 - The company will issue 1.1 million ordinary shares to three directors on December 11, 2025 [1]. - The company will also issue 25,000 ordinary shares to one employee on the same date [1]. - Both issuances are part of the pre-IPO share option plan adopted on March 29, 2021 [1].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫脈通科技有限公司 呈交日期： 2025年12月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02192 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | ...

Group 1 - The core point of the article is that the fund has increased its stake in the company, indicating confidence in its future performance [1] - On December 8, the fund acquired 2.7925 million shares of the company at a price of HKD 9.6336 per share, totaling approximately HKD 26.9018 million [1] - After the acquisition, the fund's total shareholding in the company reached 39.352 million shares, representing a 5.36% ownership stake [1]

香港联交所最新数据显示，12月8日，富国基金增持医脉通(02192)279.25万股，每股作价9.6336港元， 总金额约为2690.18万港元。增持后最新持股数目为3935.2万股，持股比例为5.36%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 醫脈通科技有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02192 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.00001 USD | | | 500,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.00001 USD | | | 500,000 | 本月底 ...